Tenaya Therapeutics (TNYA) Projected to Announce Earnings on Wednesday

Tenaya Therapeutics (NASDAQ:TNYA) is anticipated to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($0.10) per share and revenue of $0.80 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.13). The company had revenue of $1.11 million during the quarter, compared to analyst estimates of $10.00 million. On average, analysts expect Tenaya Therapeutics to post ($0.38) EPS for the current fiscal year and ($0.37) EPS for the next fiscal year.

Tenaya Therapeutics Stock Performance

NASDAQ:TNYA opened at $0.36 on Wednesday. The stock’s 50 day moving average price is $0.56 and its 200 day moving average price is $0.71. Tenaya Therapeutics has a 52 week low of $0.35 and a 52 week high of $1.56. The company has a market capitalization of $82.12 million, a P/E ratio of -0.68 and a beta of 2.88.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research note on Monday, October 26th. Wall Street Zen raised shares of Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.

Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.